The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Enhancing biomarker test awareness in patients with NSCLC with the 4R model
Frank Weinberg, MD, PhD, University of Illinois Chicago, Chicago, IL, explores the impact of the 4R Oncology model on improving patient awareness regarding biomarker testing timing and its purpose in non-small cell lung cancer (NSCLC) care. The 4R model focuses on providing the right information and care to patients in a timely manner, and the intervention involved personalized care plans, enhancing patient engagement and understanding. Results showed significant improvements in patient awareness and willingness to wait for biomarker test results before treatment, demonstrating the effectiveness of the 4R model in optimizing NSCLC patient care. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
